|本期目录/Table of Contents|

[1]范志刚,林焕新,柳仲秋,等.阿米福汀对鼻咽癌放射性口腔黏膜及涎腺损伤的保护作用[J].医学研究与战创伤救治(原医学研究生学报),2011,13(02):146-148.
　FAN Zhi-gang,LIN Huan-xin,LIU Zhong-qiu,et al.Protective effect of amifostine in irradiation mucositis of the oral cavity and dry mouth after nasapharyngeal carcinoma[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2011,13(02):146-148.
点击复制

阿米福汀对鼻咽癌放射性口腔黏膜及涎腺损伤的保护作用()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第13卷
期数:
2011年02期
页码:
146-148
栏目:
出版日期:
2011-03-20

文章信息/Info

Title:
Protective effect of amifostine in irradiation mucositis of the oral cavity and dry mouth after nasapharyngeal carcinoma
文章编号:
1672-271X(2011)02-0146-03
作者:
范志刚1; 林焕新2; 柳仲秋1; 贺启华1; 张淑莲1; 李 伟1
1.723000 陕西汉中，陕西汉中3201医院肿瘤放疗中心；2. 510060 广东中山，中山大学肿瘤医院放疗科
Author(s):
FAN Zhi-gang1;  LIN Huan-xin2;  LIU Zhong-qiu1;  HE Qi-hua1;  ZHANG Shu-lian1; LI Wei1
1. Hanzhong 3201 Hospital Radiation Oncologist， Hanzhong, Shanxi 723000， China;2．Department of RadiationOncology，Cancer Center，Sun Yat-segt University，Guangzhou，Guangdong 510060, China
关键词:
鼻咽癌; 阿米福汀; 口腔黏膜反应; 口干
Keywords:
NPC;  amifostine;  oral mucositis;  dry mouth
分类号:
R739.6
DOI:
-
文献标志码:
A
摘要:
目的 观察阿米福汀对鼻咽癌放射治疗后放射性口腔黏膜及涎腺损伤的保护作用。 方法 鼻咽癌患者在放疗期间，对照组予多贝氏漱口液，每天漱口4次；观察组在此基础上再予以注射阿米福汀；观察两组对放射性口腔黏膜及涎腺损伤的防治效果。结果 阿米福汀可明显延缓或减轻放射性口腔黏膜反应及口干的发生，对照组0～2级口腔黏膜反应、口干发生率分别为30.8%(8/26)和34.6%(9/26)，而阿米福汀观察组则为86.7%(26/30)和83.3%(25/30)；同时对照组的3级以上口腔黏膜反应与口干发生率为69.2%和65.4%，观察组则为13.3%和16.7%，两组口腔黏膜反应与口干程度比较差异均具有显著意义(均P＜0.05)。结论 阿米福汀是一种安全有效的放疗反应保护剂，它可减缓和减轻放射性口腔黏膜反应与口干的程度。
Abstract:
Objective To assess the radioprotective effects of amifostine on mucositis of the oral cavity and salivary gland after nasapharygeal carcinoma. Methods During radiotherapy of nasopharyngeal carcinoma, patients in the control group were subjected to Bayesian gargle mouthwash 4 times a day and treated more than a day. The patients of test group were on the basis of Amifostine injection. The patients were observed on the oral mucosa and salivary glands of radioactive injury prevention effect. Results Amifostine can significantly delay or reduce radiation-induced oral mucositis and dry mouth occurs. The control group had 0 to 2 oral mucositis, dry mouth rates were 30.8%(8/26) and 34.6%(9/26). In amifostine test group mucositis, dry mouth rates were 86.7%(26/30) and 70.0%(25/30). In the control group, three or more oral mucositis and dry mouth rate were 69.2% and 65.4%. In test group, three or more oral mucositis and dry mouth rate were 13.3% and 16.7%. There were significant differences both oral mucositis and dry mouth between two groups (P<0.05). Conclusion Amifostine is safe and effective radioactive protectant. It not only mitigated but also relieved the irradiation mucositis of the oral cavity and dry mouth.

参考文献/References:

[1]龚春贵.辨证治疗鼻咽癌放疗毒副反应及体会[J].东南国防医药, 2004,6(2):97-98.
[2]Veerasarn V, Phromratanapongse P, Suntornpong N，et al. Effect of amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function [J]. J Med Assoc Thai，2006,89(12):2056-2067.
[3]孟柳燕.头颈部癌患者放疗后的口腔并发症及防治措施[J].口腔医学研究，2005，19(6):526-527.
[4]Brizel DM.Pharmacologic approaches to radiation protection [J]. J Clin Oncol, 2007,25(26):4084-4089.
[5]Kouvaris JR, Kouloulias VE, Vlahos LJ， et al. Amifostine: the first selective-target and broad-spectrum radioprotector [J]. Oncologist, 2007,12(6):738-747.
[6]Rasey JS, Grunbaum Z, Krohn KA,et al. Biodistribution of the radioprotective drug 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR77913) [J].Radiat Res,1985,102(1):130-137.
[7]Brizel DM, Wasserman TH， Henke M, et al. Phase Ⅲ randomized trial of amifostine as a radioprotector in head and neck cancer [J]. J Clin Oncol, 2000, 18 (19): 3339-3345.
[8]Antonadou D, Pepelassi M, Synodinou M,et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer [J]. Int J Radiat Oncol Biol Phys， 2002,52(3):739-747.

相似文献/References:

[1]艾书跃,吴建伟,吕毛古,等.双时相18F -氟代脱氧葡萄糖PET/CT 在鼻咽癌诊断中的应用价值[J].医学研究与战创伤救治(原医学研究生学报),2009,11(04):329.
　AI Shu-yue,WU Jian-wei,LV Mao-gu,et al.The applied value of Two-Phase 18F-fluorodeoxyglucose PET/CT in diagnosis of Nasopharyngeal Carcinoma[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(02):329.
[2]蒋静.鼻咽癌化疗患者恶心呕吐的护理[J].医学研究与战创伤救治(原医学研究生学报),2009,11(05):404.
[3]陈争明,范静平,林顺涨,等.枢丹治疗鼻咽癌化疗消化道反应疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2008,10(03):206.
[4]陈贤明,黄少华,杨 帆,等.影响鼻咽癌预后的相关因素分析[J].医学研究与战创伤救治(原医学研究生学报),2014,16(06):584.[doi:10.3969/j.issn.1672-271X.2014.06.008]
　CHEN Xian-ming,HUANG Shao-hua,YANG Fan,et al.Analysis of factors related to the NPC patients prognosis[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2014,16(02):584.[doi:10.3969/j.issn.1672-271X.2014.06.008]
[5]王茂鑫,陈贤明,张贤,等.环指蛋白8在鼻咽癌组织中的表达及其与预后的关系[J].医学研究与战创伤救治(原医学研究生学报),2019,21(02):147.[doi:10.3969/j.issn.1672-271X.2019.02.007]
　WANGMao-xin,CHENXian-ming,ZHANGXian,et al.Expression of RNF8 in nasopharyngeal carcinoma and its relationship with prognosis[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2019,21(02):147.[doi:10.3969/j.issn.1672-271X.2019.02.007]
[6]洪君,张艳,张晓晔,等.不同测量方法对鼻咽癌容积调强弧形治疗验证通过率的影响[J].医学研究与战创伤救治(原医学研究生学报),2020,22(4):414.[doi:10.3969/j.issn.1672-271X.2020.04.018]
[7]王茂鑫,陈贤明,龚宏勋,等.siRNA沉默环指蛋白8基因对裸鼠人鼻咽癌移植瘤放疗增敏作用的实验研究[J].医学研究与战创伤救治(原医学研究生学报),2021,23(03):244.[doi:10.3969/j.issn.1672-271X.2021.03.005]
　WANG Mao-xin,CHEN Xian-ming,GONG Hong-xun,et al.Silencing RNF8 by siRNA enhances the radiation sensitivity of NPC transplantation tumor in nude mice[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(02):244.[doi:10.3969/j.issn.1672-271X.2021.03.005]
[8]华羽晨,唐媛媛,黄晓萍,等.耳穴贴压技术联合康复新液改良式喷雾给药在鼻咽癌放疗患者中的应用[J].医学研究与战创伤救治(原医学研究生学报),2022,24(5):537.[doi:10.3969/j.issn.1672-271X.2022.05.020]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2011-03-20